查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598700

結核病藥物市場：按疾病、藥物類別分類 - 全球預測 2025-2030 年

Tuberculosis Drugs Market by Disease (Active TB, Latent TB), Drug Class (Combination Drugs, First-line Anti-TB Drugs, Second-line Anti-TB Drugs) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年結核病藥物市場價值為19.2億美元，預計到2024年將達到20.4億美元，複合年成長率為6.28%，到2030年預計將達到29.5億美元。

結核病（TB）藥物的市場範圍包括用於預防、治療和控制結核感染的治療方法。全球結核病負擔使得使用抗結核藥物成為必要，結核病每年影響數百萬人，並且仍然是一個主要的公共衛生問題。這些藥物主要用於醫院、診所和專門的醫療保健機構，用於治療潛伏性和活動性結核病。典型的最終用戶包括醫療保健提供者、政府衛生機構和致力於根除疾病的非政府組織。該市場受到抗藥性結核分枝桿菌增加、政府預算增加以及促進早期診斷和治療依從性的宣傳活動的影響。藥物研究的進步，特別是毒性較小、活性較高、起效較快的治療方案的開發，帶來了潛在的商機。各國政府和國際衛生組織應利用這些機會，促進官民合作關係並投資研發。然而，挑戰依然存在，包括治療時間長短、目前治療方法的副作用以及結核病最受歡迎的低收入社區的財務限制。此外，多重抗藥性 (MDR) 和廣泛抗藥性 (XDR) 結核病的出現構成了主要障礙，需要創新的解決方案。研究和開發應著重於開發新的藥物化合物、診斷方法和疫苗研究，以減緩傳播。整合到結核病管理系統中的數位健康平台有可能顯著提高治療通訊協定的依從性並改善患者的治療結果。結核病藥物市場仍然複雜，監管環境不斷波動，醫療基礎設施多樣化，並且持續的社會經濟因素影響著獲得所需治療的機會。企業應專注於與研究機構的合作，並致力於創新主導的經營模式，以在新興市場佔據主導，因為這些市場對結核病藥物的需求仍然存在大量未被滿足的情況。作為一個以創新和挑戰為特徵的市場，需要採取策略方法來有效地為全球消滅結核病工作做出貢獻。

主要市場統計
基準年[2023] 19.2億美元
預計年份 [2024] 20.4億美元
預測年份 [2030] 29.5億美元
複合年成長率（%） 6.28%

市場動態：快速發展的結核病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變結核病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球抗藥結核病計畫將促進診斷和治療登記。
    • 愛滋病毒負擔增加了 LTBI 感染人數
    • 結核病患率上升
  • 市場限制因素
    • 耐多藥和廣泛抗藥性結核病藥物高成本
  • 市場機會
    • 加大開發新藥研發力度
    • 政府機構活性化結核病宣導活動
  • 市場挑戰
    • 結核病藥物的副作用

波特五力：駕馭結核病藥物市場的策略工具

波特的五力架構是了解結核病藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對結核病藥物市場的影響

外部宏觀環境因素在塑造結核病藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解結核病藥物市場的競爭狀況

結核病藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 結核病藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估結核病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為結核病治療藥物市場的成功指明道路

對於旨在加強在全球市場的影響力的公司來說，結核病藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球抗藥結核病計畫促進診斷和治療登記
      • 愛滋病毒負擔增加了 LTBI 病例數量
      • 結核病患率上升
    • 抑制因素
      • 耐多藥和廣泛抗藥性結核病藥物高成本
    • 機會
      • 加大開發新藥研發力度
      • 政府機構擴大結核病宣傳活動
    • 任務
      • 結核病藥物的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章結核病藥物市場：依疾病分類

  • 活動性結核病
  • 潛伏性結核病

第7章依藥物類別分類的結核病藥物市場

  • 伴隨藥物
  • 一線抗結核藥物
    • 乙胺丁醇
    • 異煙肼
    • Pyrazinamide
    • 利福平
  • 二線抗結核藥
    • 捲曲黴素
    • 乙硫異煙胺
    • levofloxacin
    • 鏈黴素

第8章北美和南美結核病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太結核病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章：歐洲、中東和非洲結核病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company
Product Code: MRR-03252A5F9277

The Tuberculosis Drugs Market was valued at USD 1.92 billion in 2023, expected to reach USD 2.04 billion in 2024, and is projected to grow at a CAGR of 6.28%, to USD 2.95 billion by 2030.

The market scope for Tuberculosis (TB) drugs encompasses therapeutic treatments used for the prevention, treatment, and control of tuberculosis infections. The application of TB drugs is necessitated by the global burden of TB, which remains a significant public health issue, with millions affected annually. These drugs are primarily implemented in hospitals, clinics, and specialty healthcare facilities, addressing both latent and active TB. Key end-users include healthcare providers, government health bodies, and non-governmental organizations focused on disease eradication. The market is influenced by growth in the incidence of drug-resistant TB strains, increased government funding, and awareness campaigns promoting early diagnosis and treatment adherence. Potential opportunities arise from advancements in drug research, particularly in developing less-toxic, more potent, and faster-acting regimens. Governments and global health organizations should leverage these opportunities by fostering public-private partnerships and investing in R&D. Challenges remain, however, such as the lengthy duration of treatment, side effects of current therapies, and financial constraints in low-income regions where TB is most prevalent. Moreover, the emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) TB poses significant hurdles, necessitating innovative solutions. Innovation should focus on the development of novel drug compounds, diagnostics, and vaccine research to mitigate the spread. Digital health platforms integrated into TB management systems could vastly improve adherence to treatment protocols and enhance patient outcomes. The TB drugs market remains complex, marked by fluctuating regulatory landscapes, diverse healthcare infrastructure levels, and persistent socio-economic factors affecting access to needed medications. Companies should target innovation-driven business models, emphasizing partnerships with research institutions to lead in emerging markets where the unmet need for TB drugs remains vast. As a market characterized by innovation and challenges, it requires a strategic approach to effectively contribute to global TB eradication efforts.

KEY MARKET STATISTICS
Base Year [2023] USD 1.92 billion
Estimated Year [2024] USD 2.04 billion
Forecast Year [2030] USD 2.95 billion
CAGR (%) 6.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Drugs Market

The Tuberculosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Global plan against drug-resistant TB drives diagnosis and treatment enrollment
    • HIV burden fuels LTBI case counts
    • Rising prevalence of tuberculosis
  • Market Restraints
    • High cost of MDR and XDR TB drugs
  • Market Opportunities
    • Increasing research & development of new drug development
    • Growing initiative from government organization for tuberculosis awareness
  • Market Challenges
    • Adverse side effects of tuberculosis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Drugs Market

A detailed market share analysis in the Tuberculosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Drugs Market

A strategic analysis of the Tuberculosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Company.

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease, market is studied across Active TB and Latent TB.
  • Based on Drug Class, market is studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs. The First-line Anti-TB Drugs is further studied across Ethambutol, Isoniazid, Pyrazinamide, and Rifampin. The Second-line Anti-TB Drugs is further studied across Capreomycin, Ethionamide, Levofloxacin, and Streptomycin.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Global plan against drug-resistant TB drives diagnosis and treatment enrollment
      • 5.1.1.2. HIV burden fuels LTBI case counts
      • 5.1.1.3. Rising prevalence of tuberculosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of MDR and XDR TB drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development of new drug development
      • 5.1.3.2. Growing initiative from government organization for tuberculosis awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects of tuberculosis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tuberculosis Drugs Market, by Disease

  • 6.1. Introduction
  • 6.2. Active TB
  • 6.3. Latent TB

7. Tuberculosis Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Combination Drugs
  • 7.3. First-line Anti-TB Drugs
    • 7.3.1. Ethambutol
    • 7.3.2. Isoniazid
    • 7.3.3. Pyrazinamide
    • 7.3.4. Rifampin
  • 7.4. Second-line Anti-TB Drugs
    • 7.4.1. Capreomycin
    • 7.4.2. Ethionamide
    • 7.4.3. Levofloxacin
    • 7.4.4. Streptomycin

8. Americas Tuberculosis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Tuberculosis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Tuberculosis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bristol Myers Squibb Company
  • 5. Cipla Limited
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lupin Limited
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Otsuka Pharmaceutical Co., Ltd.
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company

LIST OF FIGURES

  • FIGURE 1. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. TUBERCULOSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUBERCULOSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023